Vice advisor, The Affiliated Hospital of Qingdao University, China
Dr. Jie Lu is a distinguished medical researcher and Associate Professor at The Affiliated Hospital of Qingdao University. With a strong background in internal medicine, endocrinology, and metabolism, Dr. Lu has made significant contributions to the field of hyperuricemia and gout research. His expertise in molecular and clinical studies has led to groundbreaking findings, including the development of a spontaneous hyperuricemia mouse model and critical insights into the relationship between hyperuricemia and metabolic disorders. His research has been widely recognized, earning him prestigious awards and global collaborations.
Publication Profile
🎓 Education
Dr. Jie Lu completed his MD and PhD in Internal Medicine from Qingdao University (2015-2018), following an MS in Endocrine and Metabolism (2012-2015) from the same institution. His academic journey began with a Bachelor’s in Medicine from Shandong Second Medical University (2007-2012), laying a strong foundation for his career in medical research.
👨🔬 Experience
Dr. Lu has been serving as an Associate Professor at The Affiliated Hospital of Qingdao University since 2022. Prior to this, he worked as a Research Fellow at the same institution (2018-2022), where he played a pivotal role in advancing hyperuricemia research. His international training experience spans institutions such as the University of Otago, Henry Ford Immunology Program in the USA, and the Chinese Academy of Sciences, enriching his expertise in bioinformatics, immunology, and molecular biology.
🏆 Awards and Honors
Dr. Lu’s excellence in medical research has been recognized through numerous prestigious awards. In 2022, he received the 13th Qingdao Youth Science and Technology Award. His contributions to scientific progress earned him the First Award of Shandong Province Science and Technology Progress in 2020. Throughout his academic career, he has been honored with multiple scholarships, including the National Graduate Scholarship (2017), Excellent Student Scholarship (2016-2017), and Freshman Scholarship (2015). His outstanding performance as a researcher and student has been acknowledged with multiple “Excellent Graduate” awards from Shandong Province and Qingdao University.
🔬 Research Focus
Dr. Lu’s research is dedicated to understanding the clinical and molecular mechanisms of hyperuricemia and gout. His pioneering work in constructing a spontaneous hyperuricemia mouse model has provided invaluable insights into disease progression and treatment strategies. His studies explore the relationship between hyperuricemia and renal function, diabetes, and arterial sclerosis, with high-impact publications in leading journals such as Nature Reviews Rheumatology, Kidney International, and Diabetes. He has also been instrumental in identifying the impact of COVID-19 vaccination on gout attacks, proposing colchicine as a preventive treatment.
🏁 Conclusion
Dr. Jie Lu is a leading researcher in hyperuricemia and gout, with a remarkable academic and research career. His extensive publications, international collaborations, and pioneering research have significantly contributed to the medical field. Recognized for his scientific achievements, Dr. Lu continues to make impactful discoveries that shape the future of metabolic disease treatment.
📚 Publications
Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination – Annals of the Rheumatic Diseases, 2022 🔗
Mouse models for human hyperuricaemia: a critical review – Nature Reviews Rheumatology, 2019 🔗
Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders – Kidney International, 2018 🔗
Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic β-cell death in uricase-deficient male mice – Diabetes, 2020 🔗
Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model – The FEBS Journal, 2019 🔗
Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion – Arthritis Rheumatol, 2022 🔗
Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares – Arthritis Rheumatol, 2023 🔗
Profiling of Serum Oxylipins Identifies Distinct Spectrums and Potential Biomarkers in Young People with Very Early Onset Gout – Rheumatology (Oxford), 2023 🔗
Effects of fenofibrate therapy on renal function in primary gout patients – Rheumatology (Oxford), 2021 🔗
Trends in the manifestations of 9754 gout patients in a Chinese clinical center: A 10-year observational study – Joint Bone Spine, 2020 🔗